Cell therapy (CAR-T) · Kills target cells, directed at B-cell maturation antigen (TNFRSF17) · developed by Caribou Biosciences
CB-011 is an allogeneic, CRISPR-edited off-the-shelf CAR-T cell therapy carrying an anti-BCMA chimeric antigen receptor. The cells recognize BCMA-expressing tumor cells and kill them through cytotoxic T-lymphocyte activity. It is studied in relapsed or refractory multiple myeloma, with cyclophosphamide and fludarabine given for lymphodepletion.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05722418 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Recruiting | CRBU |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Multiple Myeloma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRBU page.
See CRBU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRBU catalysts and pipeline →